China's Brii Biosciences interim net loss narrows on lower R&D expenses

Brii Biosciences

21/08/2026 24:14

Overview
China biotech firm's interim net loss narrowed for six months ended June 30, 2026
Lower R&D and administrative expenses contributed to reduced interim loss
Company advanced HBV program and RNA-based technology platforms during period

Outlook
Company expects detailed data from ENRICH and ENHANCE studies in second half of 2026
Brii Biosciences remains focused on advancing HBV portfolio and internally discovered pipeline
Company says strong cash position and optimized structure support ongoing R&D investment
Brii Bio expects RMB1.77 bln cash to fund late-stage, RNA platform and discovery programs through 2029

Result Drivers
LOWER R&D EXPENSES - Co said decrease in R&D expenses was mainly due to organizational optimization, compensation adjustments, and reduced third-party contracting costs
LOWER ADMINISTRATIVE EXPENSES - Co said administrative expenses declined mainly due to lower employee costs and professional fees
HBV PROGRAM ADVANCEMENT - Co advanced HBV program with clinical data and presented end-of-study results from Phase 2b ENSURE study

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Loss Attributable to Owners
 
RMB 100.60 mln
 

Reuters Recommended Reads
Aug 20 - China's top drugmaker Hengrui sees profit growth squeezed by bulk-buying programs
Aug 19 - China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up
Aug 20 - China's Simcere Pharmaceutical H1 revenue rises on neuroscience, autoimmune drugs strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)